Protea Biosciences (PRGB) 0.1500 $PRGB
Protea Announces Second Quarter 2016 Results
GlobeNewswire - Tue Aug 16, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea"
released its Q2 2016 results today, reporting revenue of $581,764, a 20% increase over revenue reported for the first quarter of 2016, and revenue for the first six months of 2016 of $1,057,102, an increase of 20% over the first six months of 2015.
Protea Announces First Quarter 2016 Results
GlobeNewswire - Mon May 16, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" released its Q1 2016 results today, reporting revenue of $475,338, a 22% increase over the revenue reported for the first quarter of 2015. Revenue increases were posted for all business lines.
Protea announces license agreement with Yale
GlobeNewswire - Mon Apr 25, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" announced today that it had entered into an exclusive license agreement with Yale University for new technology to improve the differential diagnosis of malignant melanoma.
New Potential Lung Cancer Biomarkers Identified
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Protea Biosciences Group, Inc., (OTCQB RGB) announced the use of its proprietary bioanalytical technology to achieve the molecular profiling of live tumor cells while they are under treatment.
Protea Announces 2015 Year End Results
GlobeNewswire - Wed Mar 16, 4:00PM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" released its FY2015 results today, reporting total revenue of $2,003,286, an increase of 13% over FY2014 revenue of $1,768,312. The revenue growth came from its core bioanalytical services business, which grew to $929,076 in FY2015, an increase of 84% over FY2014 sales of $504,750. Additional revenue includes LAESI instrument and consumable product revenue of $932,726 and $141,484 from the Company's ongoing DARPA research grant with GWU, GE Global Research and SRI International.
Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue
ACCESSWIRE - Thu Jan 28, 8:26AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), recently announced an exclusive co-marketing agreement with Pressure BioSciences, Inc. (OTCQB: PBIO). PBIO is a worldwide leader in the development and sale of pressure cycling technology (PCT)-based sample preparation systems to the life sciences research market. Under the agreement, the companies will jointly promote PBIO's PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation, a crucial step performed by hundreds of thousands of research laboratories worldwide. This combination of technologies could result in superior biological insights and discoveries in the life sciences industry, and in rapid and dramatic revenue growth for PBIO.
NSTG: 16.38 (-0.17), A: 48.36 (+0.08), TMO: 154.64 (-0.33), NEO: 8.07 (+0.05), QGEN: 27.30 (-0.27), DHR: 80.97 (+0.27), WAT: 158.60 (+0.37)
2016 Analysis of the Global Mass Spectrometry Market - 2012-2022 - Emerging Technologies Empower Scientists
M2 - Tue Jan 26, 6:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/483nn2/analysis_of_the) has announced the addition of the "Analysis of the Global Mass Spectrometry Market" report to their offering. This research service analyzes the global mass spectrometry market. The product segments covered include single quadrupole LC-MS, tandem quadrupole LC-MS, GC-MS, TOF LC-MS, ICP-MS, and MALDI-TOF MS. End-user groups have been divided into the academia and government, pharma/biopharmaceuticals, industrial sectors, and applied markets. Revenue forecasts have been provided for product segments and end users from 2012 through 2022. Regionally, the market has been segmented into North America, Europe, and Asia-Pacific/Rest of the World. The study also offers distribution channel and competitive analyses, discusses the key market drivers and restraints, and provides prevalent market and technology trends. Key Findings - In terms of geographical segmentation, North America is expected to account for the largest share of the market followed by Europe, Asia-Pacific (APAC), and Rest of the World (RoW). Technological advancements, adoption of mass spectrometry instruments in new applications in the applied markets, and early clinical acceptance will drive the developed markets such as the United States and Europe. - Triple quadrupole instruments are best suited for applications where there is a need for increased sensitivity and specificity. - The global mass spectrometry market is moving away from traditional to high resolution based technologies such as the Quadrupole-Time of Flight (Q-TOF) mass spectrometry. - The Matrix Assisted Laser Desorption/Ionization (MALDI)-TOF segment is expected to grow at a faster rate due to its increasing adoption in clinical diagnostics applications, as it offers improved resolution, accuracy, and sensitivity. - The pharmaceutical industry accounts for the largest share of mass spectrometry instrument sales due to the need to improve drug safety and reduce costs associated with drug discovery and development processes. - Advancements in mass spectrometry technologies, continuous new product launches by major participants, increasing regulations surrounding the food testing industry, growing government support in funding for research activities, and rising uptake in the life science and clinical analysis sector are the key factors driving the demand for mass spectrometers. - Globally, the market has undergone a number of mergers and acquisitions (M&As) and also seen an increase in co-marketing and partnership agreements among companies with an objective to capture the market share at an early stage by launching advanced solutions for the clinical arena. - APAC is expected to experience higher growth rates for the mass spectrometry market over the coming years due to the increasing support and funding from the corresponding governments for research activities. Key Questions This Study Will Answer - Is the market growing? How long will it continue to grow, and at what rate? - What are the key market trends? - Which of the technology segments are presenting major growth opportunities? - What is driving the global mass spectrometry market and what are the challenges to market growth? - Who are the key vendors in the global mass spectrometry market? - Are the vendors in the space ready to go it alone, or do they need partnerships to take their businesses to the next level? Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Key Emerging Technologies - Company Profiles 4. Drivers and Restraints - Total Mass Spectrometry Market 5. Forecast and Trends - Total Mass Spectrometry Market 6. Market Share and Competitive Analysis - Total Mass Spectrometry Market 7. Mega Trends and Industry Convergence Implications - Total Mass Spectrometry Market 8. Single Quadrupole LC-MS Segment Analysis 9. Tandem LC-MS Segment Analysis 10. GC-MS Segment Analysis 11. TOF LC-MS Segment Analysis 12. MALDI-TOF MS Segment Analysis 13. ICP-MS Segment Analysis 14. North America Breakdown 15. Europe Breakdown 16. APAC and ROW Breakdown 17. India Breakdown 18. Market Share Analysis - Indian Mass Spectrometry Market Companies Mentioned - Microsaic Systems Plc - Protea Biosciences Group Inc. For more information visit http://www.researchandmarkets.com/research/48...sis_of_the
Protea to Present at Biotech Showcase(TM) 2016
GlobeNewswire - Tue Jan 05, 7:00AM CST
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea", "the Company" announced today that Stephen Turner, CEO and Chairman, will be presenting at the Biotech Showcase(TM) 2016 Conference being held in San Francisco, CA January 11 - 13, 2016.
Protea: A High Quality Small-Cap to Ride Out Biotech's Drop
ACCESSWIRE - Mon Oct 12, 8:16AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 12, 2015 / The SPDR S&P Biotech ETF (ARCA: XBI) has fallen more than 20% over the past three months, which significantly outpaced the S&P 500's 4.7% fall over the same timeframe. With the House of Representatives subpoenaing Valeant Pharmaceuticals International Inc. (NYSE: VRX) for documents related to drug price increases, the market is concerned that the federal government may be stepping up its efforts to curb increases in drug prices.
VRX: 29.82 (+3.22), FMI: 23.94 (-0.54), XBI: 62.02 (-0.27), WAT: 158.60 (+0.37), VRX.TO: 38.34 (+4.15)
Protea Offers Compelling Value Proposition to Investors
ACCESSWIRE - Thu Sep 24, 8:25AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 24, 2015 / The best biotech opportunities disrupt large and established markets with new technologies capable of improving efficacy and/or lowering cost. For example, Intuitive Surgical Inc.'s (NASDAQ: ISRG) built a multi-billion-dollar business by making surgical robots - known as Da Vinci Systems - capable of executing a greater number of procedures with a high level of precision, while making surgeries much less invasive in nature for patients.
ISRG: 683.21 (-2.83), TMO: 154.64 (-0.33), AFFX: 14.01 (+0.02)
Protea Commences REDIchip Shipments
GlobeNewswire - Tue Aug 04, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" announced today that it has commenced shipments of a new, proprietary, silicon nanochip, known as REDIchip, that reduces the time to identify and quantify small molecules in biofluids. Initial shipments have been made to customers in North America, Europe and Asia.
Protea Highlights New Mass Spec Imaging and Bioanalytical Workflows at ASMS
Marketwired - Mon Jun 01, 7:57AM CDT
Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea" announced today that it is presenting a variety of new applications using the Company's proprietary mass spec imaging system and bioanalytical workflows at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The eight posters to be presented by Protea scientists include the following:
Protea Announces Commercial Release of REDIchip(TM)
Marketwired - Mon Jun 01, 7:57AM CDT
Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea" announced today that it is launching a new chip-based technology at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The nanopost array technology, called REDIchip(TM) (Resonance-Enhanced Desorption Ionization), was invented in the laboratory of Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea.
Protea Launches New Mass Spec Technology
GlobeNewswire - Mon Jun 01, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" announced today a new, silicon chip technology that enables the rapid identification and quantitation of small molecules in biofluids. The announcement was made at the 63 American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO.
Protea Announces Completion of Private Placement
GlobeNewswire - Mon Apr 27, 2:00PM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" announced today that it has closed on total gross proceeds of $7,415,551 million from the private placement offering of preferred stock and 3-year warrants to existing and new accredited investors, which included the conversion of $2,146,977 of existing loans from shareholders. (The preferred stock has subsequently converted into common stock.) The Company will use the proceeds to provide working capital for general corporate purposes, including the ongoing expansion of bioanalytical services and core technology development.
Protea to acquire vivoPharm and intends to develop and market new services for pharmaceutical R&D
M2 - Tue Apr 07, 7:19AM CDT
Molecular information company Protea Biosciences Group (OTCBB RGB) on Tuesday disclosed that it has entered into an agreement to acquire vivoPharm Pty for an undisclosed amount.
Protea Announces Agreement to Acquire vivoPharm
GlobeNewswire - Tue Apr 07, 6:30AM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" announced today that it has entered into an agreement dated as of March 31, 2015 for the purchase of vivoPharm Pty Ltd. ("vivoPharm" , a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models.
Protea Announces Second Quarter 2016 Results
GlobeNewswire - Tue Aug 16, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" released its Q2 2016 results today, reporting revenue of $581,764, a 20% increase over revenue reported for the first quarter of 2016, and revenue for the first six months of 2016 of $1,057,102, an increase of 20% over the first six months of 2015. Protea Announces First Quarter 2016 Results
GlobeNewswire - Mon May 16, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" released its Q1 2016 results today, reporting revenue of $475,338, a 22% increase over the revenue reported for the first quarter of 2015. Revenue increases were posted for all business lines. Protea announces license agreement with Yale
GlobeNewswire - Mon Apr 25, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that it had entered into an exclusive license agreement with Yale University for new technology to improve the differential diagnosis of malignant melanoma. New Potential Lung Cancer Biomarkers Identified
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Protea Biosciences Group, Inc., (OTCQB
RGB) announced the use of its proprietary bioanalytical technology to achieve the molecular profiling of live tumor cells while they are under treatment. Protea Announces 2015 Year End Results
GlobeNewswire - Wed Mar 16, 4:00PM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" released its FY2015 results today, reporting total revenue of $2,003,286, an increase of 13% over FY2014 revenue of $1,768,312. The revenue growth came from its core bioanalytical services business, which grew to $929,076 in FY2015, an increase of 84% over FY2014 sales of $504,750. Additional revenue includes LAESI instrument and consumable product revenue of $932,726 and $141,484 from the Company's ongoing DARPA research grant with GWU, GE Global Research and SRI International. Pressure BioSciences' SCIEX Deal Could Dramatically Accelerate Revenue
ACCESSWIRE - Thu Jan 28, 8:26AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), recently announced an exclusive co-marketing agreement with Pressure BioSciences, Inc. (OTCQB: PBIO). PBIO is a worldwide leader in the development and sale of pressure cycling technology (PCT)-based sample preparation systems to the life sciences research market. Under the agreement, the companies will jointly promote PBIO's PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation, a crucial step performed by hundreds of thousands of research laboratories worldwide. This combination of technologies could result in superior biological insights and discoveries in the life sciences industry, and in rapid and dramatic revenue growth for PBIO.
NSTG: 16.38 (-0.17), A: 48.36 (+0.08), TMO: 154.64 (-0.33), NEO: 8.07 (+0.05), QGEN: 27.30 (-0.27), DHR: 80.97 (+0.27), WAT: 158.60 (+0.37)
2016 Analysis of the Global Mass Spectrometry Market - 2012-2022 - Emerging Technologies Empower Scientists
M2 - Tue Jan 26, 6:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/483nn2/analysis_of_the) has announced the addition of the "Analysis of the Global Mass Spectrometry Market" report to their offering. This research service analyzes the global mass spectrometry market. The product segments covered include single quadrupole LC-MS, tandem quadrupole LC-MS, GC-MS, TOF LC-MS, ICP-MS, and MALDI-TOF MS. End-user groups have been divided into the academia and government, pharma/biopharmaceuticals, industrial sectors, and applied markets. Revenue forecasts have been provided for product segments and end users from 2012 through 2022. Regionally, the market has been segmented into North America, Europe, and Asia-Pacific/Rest of the World. The study also offers distribution channel and competitive analyses, discusses the key market drivers and restraints, and provides prevalent market and technology trends. Key Findings - In terms of geographical segmentation, North America is expected to account for the largest share of the market followed by Europe, Asia-Pacific (APAC), and Rest of the World (RoW). Technological advancements, adoption of mass spectrometry instruments in new applications in the applied markets, and early clinical acceptance will drive the developed markets such as the United States and Europe. - Triple quadrupole instruments are best suited for applications where there is a need for increased sensitivity and specificity. - The global mass spectrometry market is moving away from traditional to high resolution based technologies such as the Quadrupole-Time of Flight (Q-TOF) mass spectrometry. - The Matrix Assisted Laser Desorption/Ionization (MALDI)-TOF segment is expected to grow at a faster rate due to its increasing adoption in clinical diagnostics applications, as it offers improved resolution, accuracy, and sensitivity. - The pharmaceutical industry accounts for the largest share of mass spectrometry instrument sales due to the need to improve drug safety and reduce costs associated with drug discovery and development processes. - Advancements in mass spectrometry technologies, continuous new product launches by major participants, increasing regulations surrounding the food testing industry, growing government support in funding for research activities, and rising uptake in the life science and clinical analysis sector are the key factors driving the demand for mass spectrometers. - Globally, the market has undergone a number of mergers and acquisitions (M&As) and also seen an increase in co-marketing and partnership agreements among companies with an objective to capture the market share at an early stage by launching advanced solutions for the clinical arena. - APAC is expected to experience higher growth rates for the mass spectrometry market over the coming years due to the increasing support and funding from the corresponding governments for research activities. Key Questions This Study Will Answer - Is the market growing? How long will it continue to grow, and at what rate? - What are the key market trends? - Which of the technology segments are presenting major growth opportunities? - What is driving the global mass spectrometry market and what are the challenges to market growth? - Who are the key vendors in the global mass spectrometry market? - Are the vendors in the space ready to go it alone, or do they need partnerships to take their businesses to the next level? Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Key Emerging Technologies - Company Profiles 4. Drivers and Restraints - Total Mass Spectrometry Market 5. Forecast and Trends - Total Mass Spectrometry Market 6. Market Share and Competitive Analysis - Total Mass Spectrometry Market 7. Mega Trends and Industry Convergence Implications - Total Mass Spectrometry Market 8. Single Quadrupole LC-MS Segment Analysis 9. Tandem LC-MS Segment Analysis 10. GC-MS Segment Analysis 11. TOF LC-MS Segment Analysis 12. MALDI-TOF MS Segment Analysis 13. ICP-MS Segment Analysis 14. North America Breakdown 15. Europe Breakdown 16. APAC and ROW Breakdown 17. India Breakdown 18. Market Share Analysis - Indian Mass Spectrometry Market Companies Mentioned - Microsaic Systems Plc - Protea Biosciences Group Inc. For more information visit http://www.researchandmarkets.com/research/48...sis_of_the
Protea to Present at Biotech Showcase(TM) 2016
GlobeNewswire - Tue Jan 05, 7:00AM CST
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea", "the Company" announced today that Stephen Turner, CEO and Chairman, will be presenting at the Biotech Showcase(TM) 2016 Conference being held in San Francisco, CA January 11 - 13, 2016. Protea: A High Quality Small-Cap to Ride Out Biotech's Drop
ACCESSWIRE - Mon Oct 12, 8:16AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 12, 2015 / The SPDR S&P Biotech ETF (ARCA: XBI) has fallen more than 20% over the past three months, which significantly outpaced the S&P 500's 4.7% fall over the same timeframe. With the House of Representatives subpoenaing Valeant Pharmaceuticals International Inc. (NYSE: VRX) for documents related to drug price increases, the market is concerned that the federal government may be stepping up its efforts to curb increases in drug prices.
VRX: 29.82 (+3.22), FMI: 23.94 (-0.54), XBI: 62.02 (-0.27), WAT: 158.60 (+0.37), VRX.TO: 38.34 (+4.15)
Protea Offers Compelling Value Proposition to Investors
ACCESSWIRE - Thu Sep 24, 8:25AM CDT
REDONDO BEACH, CA / ACCESSWIRE / September 24, 2015 / The best biotech opportunities disrupt large and established markets with new technologies capable of improving efficacy and/or lowering cost. For example, Intuitive Surgical Inc.'s (NASDAQ: ISRG) built a multi-billion-dollar business by making surgical robots - known as Da Vinci Systems - capable of executing a greater number of procedures with a high level of precision, while making surgeries much less invasive in nature for patients.
ISRG: 683.21 (-2.83), TMO: 154.64 (-0.33), AFFX: 14.01 (+0.02)
Protea Commences REDIchip Shipments
GlobeNewswire - Tue Aug 04, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that it has commenced shipments of a new, proprietary, silicon nanochip, known as REDIchip, that reduces the time to identify and quantify small molecules in biofluids. Initial shipments have been made to customers in North America, Europe and Asia. Protea Highlights New Mass Spec Imaging and Bioanalytical Workflows at ASMS
Marketwired - Mon Jun 01, 7:57AM CDT
Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea"
announced today that it is presenting a variety of new applications using the Company's proprietary mass spec imaging system and bioanalytical workflows at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The eight posters to be presented by Protea scientists include the following: Protea Announces Commercial Release of REDIchip(TM)
Marketwired - Mon Jun 01, 7:57AM CDT
Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea"
announced today that it is launching a new chip-based technology at the 63rd American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. The nanopost array technology, called REDIchip(TM) (Resonance-Enhanced Desorption Ionization), was invented in the laboratory of Akos Vertes, PhD., Department of Chemistry, The George Washington University, and exclusively licensed to Protea. Protea Launches New Mass Spec Technology
GlobeNewswire - Mon Jun 01, 7:00AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today a new, silicon chip technology that enables the rapid identification and quantitation of small molecules in biofluids. The announcement was made at the 63 American Society of Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held in St. Louis, MO. Protea Announces Completion of Private Placement
GlobeNewswire - Mon Apr 27, 2:00PM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that it has closed on total gross proceeds of $7,415,551 million from the private placement offering of preferred stock and 3-year warrants to existing and new accredited investors, which included the conversion of $2,146,977 of existing loans from shareholders. (The preferred stock has subsequently converted into common stock.) The Company will use the proceeds to provide working capital for general corporate purposes, including the ongoing expansion of bioanalytical services and core technology development. Protea to acquire vivoPharm and intends to develop and market new services for pharmaceutical R&D
M2 - Tue Apr 07, 7:19AM CDT
Molecular information company Protea Biosciences Group (OTCBB
RGB) on Tuesday disclosed that it has entered into an agreement to acquire vivoPharm Pty for an undisclosed amount. Protea Announces Agreement to Acquire vivoPharm
GlobeNewswire - Tue Apr 07, 6:30AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that it has entered into an agreement dated as of March 31, 2015 for the purchase of vivoPharm Pty Ltd. ("vivoPharm" , a global provider of pharmacology, toxicology and bioanalytical research services, with a portfolio of proprietary oncology models. 
